Suboxone Maker Settles With DOJ, FTC For Trying To Block Generic Entry

Reckitt Benckiser Group, which used to own Suboxone maker Indivior, has agreed to pay $700 million to the federal government and $50 million to settle Federal Trade Commission charges that the company violated antitrust laws in an attempt to thwart generic competition to the opioid addiction treatment drug Suboxone. In total, RB Group will pay $1.4 billion as part of a non-prosecution agreement to resolve the company’s alleged criminal and civil liability related to its marketing practices, the Department of...